Matches in Wikidata for { <http://www.wikidata.org/entity/Q57904151> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- Q57904151 description "article scientifique publié en 2016" @default.
- Q57904151 description "im Oktober 2016 veröffentlichter wissenschaftlicher Artikel" @default.
- Q57904151 description "wetenschappelijk artikel" @default.
- Q57904151 description "наукова стаття, опублікована в жовтні 2016" @default.
- Q57904151 name "Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia" @default.
- Q57904151 name "Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia" @default.
- Q57904151 type Item @default.
- Q57904151 label "Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia" @default.
- Q57904151 label "Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia" @default.
- Q57904151 prefLabel "Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia" @default.
- Q57904151 prefLabel "Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia" @default.
- Q57904151 P1433 Q57904151-107A25FE-8EF3-43FF-BA1C-D0D40B26A1FC @default.
- Q57904151 P1476 Q57904151-060F6B41-0105-4785-AB0A-4F11A5AC89DD @default.
- Q57904151 P2093 Q57904151-48AE24BD-F085-46E3-A44C-7FA94A4BD5E9 @default.
- Q57904151 P2093 Q57904151-82D63A1C-1EDA-4A3B-8560-700AC37416D5 @default.
- Q57904151 P2860 Q57904151-00FBB515-052A-48C8-8CF5-AE3F011A8681 @default.
- Q57904151 P2860 Q57904151-0F5A4123-8791-4944-A8A2-599FD5069BB3 @default.
- Q57904151 P2860 Q57904151-6559588C-F9ED-4D94-A828-FDD63DAD57DB @default.
- Q57904151 P2860 Q57904151-7B5E87CC-8F97-4A6A-955D-5A0CCC0EEA7B @default.
- Q57904151 P2860 Q57904151-8620D6B2-0FBA-4304-9980-4A33D70E10B5 @default.
- Q57904151 P2860 Q57904151-8E62C23F-5517-46BD-80EC-6B40FCB46D3A @default.
- Q57904151 P2860 Q57904151-8EF5A193-241E-43E9-B33B-A41FFDA018AE @default.
- Q57904151 P2860 Q57904151-96BDE28E-340B-4412-8094-D5E5D4EA6A82 @default.
- Q57904151 P2860 Q57904151-9DD21E62-E7CE-4611-A065-3BA84D74B3DA @default.
- Q57904151 P2860 Q57904151-A842B353-A90D-48DE-96BC-864B0DFEA7C4 @default.
- Q57904151 P2860 Q57904151-B4796A0D-6252-47B0-9559-F7B70F41DA1E @default.
- Q57904151 P2860 Q57904151-BFC4C6D2-B2A4-4817-8763-025226DC9C43 @default.
- Q57904151 P2860 Q57904151-E356C7FD-3A2B-49A6-9384-F8007FC46F73 @default.
- Q57904151 P2860 Q57904151-FC881AD0-C0AA-48F6-BA51-4959703315D8 @default.
- Q57904151 P304 Q57904151-6F1E43D8-A0C9-4826-82A7-E6EA1B886F0C @default.
- Q57904151 P31 Q57904151-71FED786-D4E4-4F74-ACA0-5CD986AD8158 @default.
- Q57904151 P356 Q57904151-3B3B6258-F299-425F-BDEB-E1E83ABE4C72 @default.
- Q57904151 P433 Q57904151-6F881ECC-F4A5-4C78-BCDE-4C0A15089AAE @default.
- Q57904151 P478 Q57904151-F5F01C7B-E2FD-497C-9354-2544150A5352 @default.
- Q57904151 P50 Q57904151-016884E7-7977-49A2-942D-59145BFF509A @default.
- Q57904151 P50 Q57904151-0E921AA7-E3D1-42AF-9B57-5639F4394B47 @default.
- Q57904151 P50 Q57904151-2537DAE1-22B7-437B-86D9-881A401B7493 @default.
- Q57904151 P50 Q57904151-4359835B-B098-48E7-80BE-32D0A20D686E @default.
- Q57904151 P50 Q57904151-7C5644F2-61F1-416C-97F9-17DE39776C81 @default.
- Q57904151 P50 Q57904151-CA1E55F2-E763-4001-95D7-FA38AB590A55 @default.
- Q57904151 P50 Q57904151-D1651CAC-FA19-4EE7-B677-72F243552C3F @default.
- Q57904151 P50 Q57904151-DBC67159-1865-4A92-91B9-9670F94138AC @default.
- Q57904151 P50 Q57904151-E4F89D84-BBF7-4C74-B672-D9FB63403603 @default.
- Q57904151 P577 Q57904151-5C77D630-6316-4F65-8776-9641C6E1E144 @default.
- Q57904151 P698 Q57904151-B53E559E-2997-4C0B-9DBA-C351264091A2 @default.
- Q57904151 P356 10428194.2016.1233541 @default.
- Q57904151 P698 27724158 @default.
- Q57904151 P1433 Q6534493 @default.
- Q57904151 P1476 "Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia" @default.
- Q57904151 P2093 "Maria Mpakiri" @default.
- Q57904151 P2093 "Theodoros P. Vassilakopoulos" @default.
- Q57904151 P2860 Q24634076 @default.
- Q57904151 P2860 Q28201685 @default.
- Q57904151 P2860 Q28237066 @default.
- Q57904151 P2860 Q33394947 @default.
- Q57904151 P2860 Q33810053 @default.
- Q57904151 P2860 Q34608608 @default.
- Q57904151 P2860 Q35116840 @default.
- Q57904151 P2860 Q35577484 @default.
- Q57904151 P2860 Q36764811 @default.
- Q57904151 P2860 Q37338703 @default.
- Q57904151 P2860 Q38029382 @default.
- Q57904151 P2860 Q38059720 @default.
- Q57904151 P2860 Q43923016 @default.
- Q57904151 P2860 Q46131613 @default.
- Q57904151 P304 "1506-1508" @default.
- Q57904151 P31 Q13442814 @default.
- Q57904151 P356 "10.1080/10428194.2016.1233541" @default.
- Q57904151 P433 "6" @default.
- Q57904151 P478 "58" @default.
- Q57904151 P50 Q114411825 @default.
- Q57904151 P50 Q114411840 @default.
- Q57904151 P50 Q26338766 @default.
- Q57904151 P50 Q43187559 @default.
- Q57904151 P50 Q51846854 @default.
- Q57904151 P50 Q57015797 @default.
- Q57904151 P50 Q85267659 @default.
- Q57904151 P50 Q88776018 @default.
- Q57904151 P50 Q94555400 @default.
- Q57904151 P577 "2016-10-10T00:00:00Z" @default.
- Q57904151 P698 "27724158" @default.